Details for Patent: RE40812
✉ Email this page to a colleague
Summary for Patent: RE40812
Title: | Nasal calcitonin formulation |
Abstract: | .[.A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration..]. .Iadd.A liquid pharmaceutical composition is provided for nasal administration of calcitonin or an acid addition salt thereof. The nasal pharmaceutical formulations contain a component selected from the group consisting of citric acid, citric acid salt and a combination thereof..Iaddend. |
Inventor(s): | Stern; William (Tenafly, NJ) |
Assignee: | Unigene Laboratories Inc. (Boonton, NJ) |
Application Number: | 10/774,358 |
Patent Claim Types: see list of patent claims | Composition; Use; |
Drugs Protected by US Patent RE40812
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE40812
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 3660401 | ⤷ Sign Up | |||
Australia | 783952 | ⤷ Sign Up | |||
Canada | 2399505 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |